SOLICITATION NOTICE
66 -- AKTA FPLC
- Notice Date
- 5/17/2007
- Notice Type
- Solicitation Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70061-NG
- Response Due
- 6/1/2007
- Archive Date
- 6/16/2007
- Description
- The National Cancer Institute (NCI) plans to procure on a sole source basis; two (2) AKTA Automated Fast Protein Liquid Chromatography Systems (FPLC), with GE Healthcare Biosciences Corporation; 800 Centennial Avenue, Piscataway, New Jersey 08855. The supplies and services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106. The North American Industry Classification System Code is 334516 and the business size standard is 500 employees. The salient characteristics apply to the AKTA FPLC Systems: Dimensions: Height: 47cm x Depth 48cm x Width 38cm; Dimensions for Frac950 are Height 48cm x Depth 55 cm x Width 38cm. -perform separations based on a variety of sample characteristics, such as molecular weight, net surface charge, hydrophobicity, or affinity while retaining biological activity; - flow rate range of 0.05-20mls/min at pressures ranging from 0-700 psi; - two-pump gradient system, with dynamic mixing; - system pumps allow operation of the system at zero backpressure to ensure system compatibility with standard low pressure chromatography supports; - controller allows programs to be time-based, volume-based, or column-volume based, and must allow user intervention of a running method (e.g., change of flow rate) without stopping or pausing the run; - system has the ability to control nine motorized valves; - system includes a fraction collector which is fully integrated into the system and fully controllable via the system control software; - Control of up to nine motorized valves, chart recorder, fraction collector, dynamic gradient mixer, air sensors, and three pumps, are all possible from the system controller; - The pumps, UV and conductivity monitors, valves and fraction collector are all specified for use in a cold room at 4 degrees C; - controller accepts seven input signals (e.g. UV wavelength, conductivity, pH, temperature, pressure); - system utilizes Pharmacia HR16/10, HR 5/5, Mono Q 5/50 GL, HiPrep 16/60 and Tosoh TSK-GE chromatography columns. - Compatibility with GEs Unicorn software system. Justification: The laboratory currently has 98 active patents related to antibody and immunotoxin design, construction and production and genes identified as potential targets for immunotherapy of cancer. Five of the laboratorys immunotoxins are currently in Phase1/Phase2 clinical trials and generate considerable research. Two of the laboratorys monoclonal antibodies are being marketed for licensing and distribution. The NCI is continuously making and improving immunotoxins and other proteins used to study their activity and effectiveness. The proteins are made in E coli and purified by FPLC. Benefit The results of such studies, as mentioned above, are expected to yield new information regarding ways to diagnose, interrupt, prevent and otherwise treat the spread of cancer. In addition, it is highly likely that the identification of novel biomarkers applicable to patient diagnostics will result. For example, preliminary studies are underway to correlate mesothelin with human ovarian, lung, and pancreatic cancer with the cancer burden using purified antibodies to mesothelin. These are expected to permit the filing of intellectual property claims based upon research performed with this instrument. The AKTA FPLC system enables the NCI to perform separations based on a variety of sample characteristics, such as molecular weight, net surface charge, hydrophobicity, or affinity while retaining biological activity. The AKTA FPLC Systems are controlled with Unicorn - GE Healthcare?s AKTA FPLC system controller software, which is already in use in the laboratory. The AKTA FPLC Systems must be able to utilize Pharmacia HR16/10, HR 5/5, Mono Q 5/50 GL, HiPrep 16/60 and Tosoh TSK-GE chromatography columns already in use in the laboratory. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office by 1:00 PM ET on June 1, 2007. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Malinda Holdcraft, Contract Specialist at holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-70061-NG on all correspondence.
- Record
- SN01296593-W 20070519/070517220542 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |